17.20

2.69% 0.45

Pre-market: 17.00 -0.20 -1.16%

Ultragenyx Pharmaceutical Inc (RARE)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Ultragenyx Pharmaceutical Inc stock is traded at $17.20, with a volume of 2.32M. It is up +2.69% in the last 24 hours and up +12.27% over the past month. Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Previous Close:

$16.75

Open:

$16.73

24h Volume:

2.32M

Relative Volume:

0.77

Market Cap:

$1.70B

Revenue:

$669.43M

Net Income/Loss:

$-609.36M

P/E Ratio:

-2.8169

EPS:

-6.1061

Net Cash Flow:

$-507.20M

1W Performance:

+7.84%

1M Performance:

+12.27%

6M Performance:

-28.87%

1Y Performance:

-50.27%

1-Day Range:

$0.00

1-Week Range:

$15.49

$17.35

52-Week Range:

$12.73

$39.89

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Name

Ultragenyx Pharmaceutical Inc

Sector

Healthcare (1052)

Industry

Biotechnology (595)

Phone

415-483-8800

Address

60 LEVERONI COURT, NOVATO, CA

Employee

1,371

Twitter

Next Earnings Date

2026-11-03

Latest SEC Filings

RARE's Discussions on Twitter

Compare RARE vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RARE Ultragenyx Pharmaceutical Inc	17.20	1.70B	669.43M	-609.36M	-507.20M	-6.1061
VRTX Vertex Pharmaceuticals Inc	529.69	134.26B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	214.16	85.50B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	813.27	83.73B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	891.76	56.08B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	373.36	42.24B	5.76B	514.49M	1.10B	4.4813

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-15-26	Initiated	UBS	Neutral
Sep-03-26	Downgrade	BofA Securities	Buy → Neutral
Sep-03-26	Downgrade	Evercore ISI	Outperform → In-line
Sep-03-26	Downgrade	JP Morgan	Overweight → Neutral
Sep-03-26	Downgrade	Robert W. Baird	Outperform → Neutral
Sep-03-26	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-03-26	Downgrade	William Blair	Outperform → Mkt Perform
Mar-24-26	Downgrade	Goldman	Buy → Neutral
Oct-20-25	Initiated	Wells Fargo	Overweight
Jul-28-25	Resumed	H.C. Wainwright	Buy
May-28-25	Initiated	William Blair	Outperform
Jun-06-24	Upgrade	Goldman	Neutral → Buy
Apr-22-24	Initiated	RBC Capital Mkts	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Jun-14-23	Resumed	Credit Suisse	Outperform
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight
Jan-18-23	Resumed	Canaccord Genuity	Buy
Dec-30-22	Resumed	H.C. Wainwright	Buy
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight
Sep-30-21	Initiated	H.C. Wainwright	Buy
Aug-19-21	Initiated	UBS	Sell
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy
Jun-04-21	Resumed	Robert W. Baird	Neutral
May-06-21	Upgrade	Citigroup	Neutral → Buy
May-06-21	Upgrade	Evercore ISI	In-line → Outperform
Apr-26-21	Resumed	Credit Suisse	Neutral
Mar-02-21	Resumed	Stifel	Buy
Feb-12-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-07-20	Downgrade	Wedbush	Outperform → Neutral
Nov-24-20	Resumed	Evercore ISI	In-line
Nov-12-20	Downgrade	BofA Securities	Buy → Neutral
Aug-02-19	Resumed	Wedbush	Outperform
Mar-27-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Feb-22-19	Resumed	Raymond James	Outperform
Jan-02-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-08-18	Upgrade	Citigroup	Sell → Neutral
Sep-10-18	Initiated	Morgan Stanley	Equal-Weight
Jun-21-18	Downgrade	Credit Suisse	Outperform → Neutral
May-11-18	Upgrade	Barclays	Equal Weight → Overweight
May-10-18	Initiated	Goldman	Neutral
Apr-18-18	Upgrade	SunTrust	Hold → Buy
Mar-22-18	Resumed	Piper Jaffray	Overweight
Feb-21-18	Reiterated	Stifel	Buy
Jan-22-18	Upgrade	Evercore ISI	In-line → Outperform
Jan-18-18	Initiated	Credit Suisse	Outperform
Dec-05-17	Reiterated	Barclays	Equal Weight
Dec-04-17	Upgrade	Jefferies	Hold → Buy
Sep-14-17	Upgrade	Wedbush	Neutral → Outperform

View All

Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News

Oct 28, 2026

Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for - Zacks Investment Research

Oct 28, 2026

GSK (GSK) Q3 Earnings and Revenues Beat Estimates - Zacks Investment Research

Oct 28, 2026

Oct 27, 2026

Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Zacks Investment Research

Oct 27, 2026

Oct 21, 2026

Form DEF 14A Ultragenyx Pharmaceutical Inc For: 21 October By Investing.com - Investing.com Australia

Oct 21, 2026

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $33.65 According to Brokerages - MarketBeat

Oct 21, 2026